Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results.

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical ...

Show” correspondent Al Madrigal returned on Thursday night with a stinging message about immigrants in the United States.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

Manfredo Madrigal Will Serve 54 Months In Federal Prison LYNCHBURG, Va. – A former Army officer and attorney assigned to the ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full ...

根据提交给美国证券交易委员会的Form 4文件显示，Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)的总法律顾问Kelley Shannon ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)研发总裁兼首席医疗官Rebecca Taub最近出售了1,689股公司普通股。这些股票以平均每股273.41美元的价格售出，交易总额约为461,789美元。根据 InvestingPro 的数据，该公司股票目前交易价格为293.64美元，过去一周下跌了13.36%。尽管近期波动，分析师仍保持看好态度，给予"买入 ...

Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers." ...